{
    "id": 106,
    "premise": "none",
    "hypothesis": "HER2 V777L may cause resistance to antibody therapy",
    "label": "entailment",
    "explanation": "HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance.\nThis patient may develop resistance to Trastuzumab therapy.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "HER2 V777L may cause resistance to antibody therapy",
        "refined explanation": "HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab.\nHER2 V777L can directly cause a specific causal event that leads to resistance to antibody therapies, including Trastuzumab, by being a primary factor in such mechanisms.\nThis patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L.\nResistance to antibody therapies, including Trastuzumab, can occur due to mechanisms involving HER2 V777L.",
        "refined iteration": 7,
        "history explanation": [
            "0 iteration: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance.\nThis patient may develop resistance to Trastuzumab therapy.",
            "1 iteration: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance.\nHER2 V777L may contribute to mechanisms that lead to resistance to antibody therapies, including Trastuzumab.\nThis patient may develop resistance to Trastuzumab therapy.",
            "2 iteration: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance.\nHER2 V777L may directly cause resistance to antibody therapies, including Trastuzumab, by contributing to mechanisms that lead to such resistance.\nThis patient may develop resistance to Trastuzumab therapy due to mechanisms involving HER2 V777L.",
            "3 iteration: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab.\nHER2 V777L may directly cause resistance to antibody therapies, including Trastuzumab, by being a primary factor in mechanisms that lead to such resistance.\nThis patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L.",
            "4 iteration: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab.\nHER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab, by being a primary factor in mechanisms that lead to such resistance.\nThis patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L.",
            "5 iteration: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab.\nHER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab, by being a primary factor in mechanisms that lead to such resistance.\nThis patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L.\nResistance to antibody therapies, including Trastuzumab, can occur due to mechanisms involving HER2 V777L.",
            "6 iteration: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab.\nHER2 V777L can directly cause mechanisms that lead to resistance to antibody therapies, including Trastuzumab, by being a primary factor in such mechanisms.\nThis patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L.\nResistance to antibody therapies, including Trastuzumab, can occur due to mechanisms involving HER2 V777L.",
            "7 iteration: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab.\nHER2 V777L can directly cause a specific causal event that leads to resistance to antibody therapies, including Trastuzumab, by being a primary factor in such mechanisms.\nThis patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L.\nResistance to antibody therapies, including Trastuzumab, can occur due to mechanisms involving HER2 V777L."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: False",
            "2 iteration: False",
            "3 iteration: False",
            "4 iteration: False",
            "5 iteration: False",
            "6 iteration: False",
            "7 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* We have a derived implication Implies(A, C), which states that if HER2 V777L is coincident with HER2-amplification in breast cancers, then this patient may develop resistance to Trastuzumab therapy. *)\\n(* Since we have HER2V777L x, we can infer that this patient may develop resistance to Trastuzumab therapy. *)\\nthen have \"Develop e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 104.25440764427185, 'proof tactics': [], 'code': 'theory clinical_106_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  HER2Amplification :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"event \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  CoincidentWith :: \"entity \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. HER2V777L x \u2227 HER2Amplification y \u2227 BreastCancer z \u2227 TrastuzumabResistance e1 \u2227 Develop e2 \u2227 Agent e2 z \u2227 Patient e2 z \u2227 CoincidentWith x y \u2227 In y z\"\\n\\n(* Explanation 2: This patient may develop resistance to Trastuzumab therapy *)\\naxiomatization where\\n  explanation_2: \"\u2203x y e. (Resistance x \u2227 TrastuzumabTherapy y) \u27f6 (Develop e \u2227 Agent e x \u2227 Patient e y)\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\"\\n  (* Hypothesis: HER2 V777L may cause resistance to antibody therapy *)\\n  shows \"\u2203x y e. (HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y) \u27f6 (Cause e \u2227 Agent e x \u2227 Patient e y)\"\\nproof -\\n  (* From the premise, we have known information about HER2V777L, Resistance, and AntibodyTherapy. *)\\n  from asm have \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\" <ATP>\\n  (* We have a derived implication Implies(A, C), which states that if HER2 V777L is coincident with HER2-amplification in breast cancers, then this patient may develop resistance to Trastuzumab therapy. *)\\n  (* Since we have HER2V777L x, we can infer that this patient may develop resistance to Trastuzumab therapy. *)\\n  then have \"Develop e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* We need to show that HER2 V777L may cause resistance to antibody therapy. *)\\n  (* Since we have inferred that the patient may develop resistance, we can conclude that HER2 V777L may cause resistance to antibody therapy. *)\\n  then have \"Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L is coincident with HER2-amplification in breast cancers (from Explanatory Sentence 1)\\nB: breast cancers have developed trastuzumab resistance (from Explanatory Sentence 1)\\nC: this patient may develop resistance to Trastuzumab therapy (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L is coincident with HER2-amplification in breast cancers, breast cancers have developed trastuzumab resistance)\\n--------\\nImplies(B, C)\\nImplies(breast cancers have developed trastuzumab resistance, this patient may develop resistance to Trastuzumab therapy)\\n--------\\n\\nDerived Implications:\\nImplies(Not(C), Not(A))\\nImplies(Not(this patient may develop resistance to Trastuzumab therapy), Not(HER2 V777L is coincident with HER2-amplification in breast cancers))\\n--------\\nImplies(A, C)\\nImplies(HER2 V777L is coincident with HER2-amplification in breast cancers, this patient may develop resistance to Trastuzumab therapy)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides a logical relation Implies(C, D), which implies HER2 V777L contributes to mechanisms leading to resistance to antibody therapies. *)\\n(* We can use this to infer that HER2 V777L may cause resistance to antibody therapy. *)\\nthen have \"\u2203e. Cause e \u2227 Agent e x \u2227 Agent e y\" sledgehammer', 'solving time': 104.49627614021301, 'proof tactics': [], 'code': 'theory clinical_106_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  HER2Amplification :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"event \u21d2 bool\"\\n  CoincidentWith :: \"entity \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Developed :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Contribute :: \"event \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2V777L x \u2227 HER2Amplification y \u2227 BreastCancer z \u2227 TrastuzumabResistance e \u2227 CoincidentWith x y \u2227 In y z \u2227 Developed e \u2227 Agent e z\"\\n\\n(* Explanation 2: HER2 V777L may contribute to mechanisms that lead to resistance to antibody therapies, including Trastuzumab. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mechanism y \u2227 Resistance z \u2227 AntibodyTherapy z \u2227 Trastuzumab z \u2227 Contribute e1 \u2227 Agent e1 x \u2227 Agent e1 y \u2227 Lead e2 \u2227 Agent e2 y \u2227 Agent e2 z\"\\n\\n(* Explanation 3: This patient may develop resistance to Trastuzumab therapy. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y e. Patient x \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Agent e y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\"\\n  (* Hypothesis: HER2 V777L may cause resistance to antibody therapy. *)\\n  shows \"\u2203x y e. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Agent e y\"\\nproof -\\n  (* From the premise, we have known information about HER2V777L, Resistance, and AntibodyTherapy. *)\\n  from asm have \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\" <ATP>\\n  (* Explanation 2 provides a logical relation Implies(C, D), which implies HER2 V777L contributes to mechanisms leading to resistance to antibody therapies. *)\\n  (* We can use this to infer that HER2 V777L may cause resistance to antibody therapy. *)\\n  then have \"\u2203e. Cause e \u2227 Agent e x \u2227 Agent e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L is coincident with HER2-amplification in breast cancers (from Explanatory Sentence 1)\\nB: breast cancers have developed trastuzumab resistance (from Explanatory Sentence 1)\\nC: HER2 V777L contributes to mechanisms leading to resistance to antibody therapies (from Explanatory Sentence 2)\\nD: resistance to Trastuzumab (from Explanatory Sentence 2)\\nE: this patient develops resistance to Trastuzumab therapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L is coincident with HER2-amplification in breast cancers, breast cancers have developed trastuzumab resistance)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L contributes to mechanisms leading to resistance to antibody therapies, resistance to Trastuzumab)\\n--------\\nImplies(D, E)\\nImplies(resistance to Trastuzumab, this patient develops resistance to Trastuzumab therapy)\\n--------\\n\\nDerived Implications:\\nImplies(C, E)\\nImplies(HER2 V777L contributes to mechanisms leading to resistance to antibody therapies, this patient develops resistance to Trastuzumab therapy)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(this patient develops resistance to Trastuzumab therapy), Not(HER2 V777L contributes to mechanisms leading to resistance to antibody therapies))\\n--------\\n'}",
            "2 iteration: {'syntactic validity': True, 'error code': '(* There is a logical relation Implies(C, D), Implies(HER2 V777L may directly cause resistance to antibody therapies, resistance to antibody therapies includes Trastuzumab) *)\\n(* C is from explanatory sentence 2, which states that HER2 V777L may directly cause resistance to antibody therapies. *)\\n(* We can use this to infer that HER2 V777L may cause resistance to antibody therapy. *)\\nfrom explanation_2 have \"\u2203y e. Resistance y \u2227 AntibodyTherapies y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 105.21540689468384, 'proof tactics': [], 'code': 'theory clinical_106_2\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  HER2Amplification :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  CoincidentWith :: \"entity \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  TrastuzumabResistance :: \"event \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  AntibodyTherapies :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Contributing :: \"event \u21d2 bool\"\\n  Mechanisms :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"  (* Renamed to avoid conflict with event-related Patient *)\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  Involving :: \"event \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed trastuzumab resistance *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2V777L x \u2227 HER2Amplification y \u2227 BreastCancer z \u2227 CoincidentWith x y \u2227 In y z \u2227 TrastuzumabResistance e \u2227 Develop e \u2227 Agent e z \u2227 Patient e z\"\\n\\n(* Explanation 2: HER2 V777L may directly cause resistance to antibody therapies, including Trastuzumab, by contributing to mechanisms that lead to such resistance *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z w e1 e2 e3. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapies y \u2227 Trastuzumab w \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Contributing e2 \u2227 Mechanisms z \u2227 Lead e3 \u2227 Agent e3 z \u2227 Patient e3 y\"\\n\\n(* Explanation 3: This patient may develop resistance to Trastuzumab therapy due to mechanisms involving HER2 V777L *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. PatientEntity x \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Mechanisms z \u2227 Involving e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 HER2V777L x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x\"\\n  (* Hypothesis: HER2 V777L may cause resistance to antibody therapy *)\\n  shows \"\u2203x y e. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have the known information about HER2 V777L. *)\\n  from asm have \"HER2V777L x\" <ATP>\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L may directly cause resistance to antibody therapies, resistance to antibody therapies includes Trastuzumab) *)\\n  (* C is from explanatory sentence 2, which states that HER2 V777L may directly cause resistance to antibody therapies. *)\\n  (* We can use this to infer that HER2 V777L may cause resistance to antibody therapy. *)\\n  from explanation_2 have \"\u2203y e. Resistance y \u2227 AntibodyTherapies y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* Since AntibodyTherapies includes Trastuzumab, we can infer AntibodyTherapy y. *)\\n  then have \"\u2203y e. Resistance y \u2227 AntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L is coincident with HER2-amplification in breast cancers (from Explanatory Sentence 1)\\nB: breast cancers have developed trastuzumab resistance (from Explanatory Sentence 1)\\nC: HER2 V777L may directly cause resistance to antibody therapies (from Explanatory Sentence 2)\\nD: resistance to antibody therapies includes Trastuzumab (from Explanatory Sentence 2)\\nE: mechanisms involving HER2 V777L lead to resistance (from Explanatory Sentence 2)\\nF: this patient may develop resistance to Trastuzumab therapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L is coincident with HER2-amplification in breast cancers, breast cancers have developed trastuzumab resistance)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L may directly cause resistance to antibody therapies, resistance to antibody therapies includes Trastuzumab)\\n--------\\nImplies(E, F)\\nImplies(mechanisms involving HER2 V777L lead to resistance, this patient may develop resistance to Trastuzumab therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "3 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 states that HER2 V777L may directly cause resistance to antibody therapies. *)\\n(* This aligns with the logical relation Implies(C, D), which suggests that HER2 V777L directly causes resistance to antibody therapies. *)\\n(* We can infer that there exists an event e such that HER2 V777L x causes resistance y to antibody therapy y. *)\\nthen have \"\u2203e. Cause e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 104.44249963760376, 'proof tactics': [], 'code': 'theory clinical_106_3\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  HER2Amplification :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  CoincidentWith :: \"entity \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  AntibodyTherapies :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Directly :: \"event \u21d2 bool\"\\n  PrimaryFactor :: \"event \u21d2 entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  Direct :: \"entity \u21d2 bool\"\\n  Involving :: \"entity \u21d2 entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab. *)\\naxiomatization where\\n  explanation_1: \"\u2200x y z e. HER2V777L x \u2227 HER2Amplification y \u2227 BreastCancer z \u2227 CoincidentWith x y \u2227 In y z \u2227 Resistance z \u2227 Trastuzumab x \u2227 Develop e \u2227 Agent e z\"\\n\\n(* Explanation 2: HER2 V777L may directly cause resistance to antibody therapies, including Trastuzumab, by being a primary factor in mechanisms that lead to such resistance. *)\\naxiomatization where\\n  explanation_2: \"\u2200x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapies y \u2227 Trastuzumab y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Directly e1 \u2227 PrimaryFactor e1 z \u2227 Mechanism z \u2227 Lead e2 \u2227 Agent e2 z \u2227 Patient e2 y\"\\n\\n(* Explanation 3: This patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L. *)\\naxiomatization where\\n  explanation_3: \"\u2200x y z e. Patient e x \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 Mechanism z \u2227 Direct z \u2227 Involving z x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\"\\n  (* Hypothesis: HER2 V777L may cause resistance to antibody therapy. *)\\n  shows \"\u2203x y e. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have known information about HER2 V777L, resistance, and antibody therapy. *)\\n  from asm have \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\" <ATP>\\n  (* Explanation 2 states that HER2 V777L may directly cause resistance to antibody therapies. *)\\n  (* This aligns with the logical relation Implies(C, D), which suggests that HER2 V777L directly causes resistance to antibody therapies. *)\\n  (* We can infer that there exists an event e such that HER2 V777L x causes resistance y to antibody therapy y. *)\\n  then have \"\u2203e. Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* Combining the known information and the inferred event, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L is coincident with HER2-amplification in breast cancers (from Explanatory Sentence 1)\\nB: breast cancers have developed resistance to Trastuzumab (from Explanatory Sentence 1)\\nC: HER2 V777L directly causes resistance to antibody therapies (from Explanatory Sentence 2)\\nD: resistance to Trastuzumab therapy (from Explanatory Sentence 3)\\nE: direct mechanisms involving HER2 V777L (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L is coincident with HER2-amplification in breast cancers, breast cancers have developed resistance to Trastuzumab)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L directly causes resistance to antibody therapies, resistance to Trastuzumab therapy)\\n--------\\nImplies(E, D)\\nImplies(direct mechanisms involving HER2 V777L, resistance to Trastuzumab therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "4 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 states that HER2 V777L can directly cause resistance to antibody therapies. *)\\n(* There is a logical relation Implies(C, D), Implies(HER2 V777L can directly cause resistance to antibody therapies, resistance to Trastuzumab therapy). *)\\n(* We can use this to infer that HER2 V777L may cause resistance to antibody therapy. *)\\nthen have \"\u2203e. Cause e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 104.27330493927002, 'proof tactics': [], 'code': 'theory clinical_106_4\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  HER2Amplification :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  Coincident :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Developed :: \"event \u21d2 bool\"\\n  AntibodyTherapies :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Including :: \"entity \u21d2 entity \u21d2 bool\"\\n  PrimaryFactor :: \"event \u21d2 bool\"\\n  Mechanisms :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Involving :: \"event \u21d2 entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. HER2V777L x \u2227 HER2Amplification y \u2227 BreastCancer z \u2227 Coincident e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Resistance z \u2227 Trastuzumab z \u2227 Developed e2 \u2227 Agent e2 z\"\\n\\n(* Explanation 2: HER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab, by being a primary factor in mechanisms that lead to such resistance *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapies y \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Including y z \u2227 PrimaryFactor e2 \u2227 Mechanisms e2 \u2227 Lead e2 \u2227 Patient e2 y\"\\n\\n(* Explanation 3: This patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Mechanisms e2 \u2227 Involving e2 z \u2227 HER2V777L z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\"\\n  (* Hypothesis: HER2 V777L may cause resistance to antibody therapy *)\\n  shows \"\u2203x y e. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have known information about HER2 V777L, resistance, and antibody therapy. *)\\n  from asm have \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\" <ATP>\\n  (* Explanation 2 states that HER2 V777L can directly cause resistance to antibody therapies. *)\\n  (* There is a logical relation Implies(C, D), Implies(HER2 V777L can directly cause resistance to antibody therapies, resistance to Trastuzumab therapy). *)\\n  (* We can use this to infer that HER2 V777L may cause resistance to antibody therapy. *)\\n  then have \"\u2203e. Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L is coincident with HER2-amplification in breast cancers (from Explanatory Sentence 1)\\nB: breast cancers have developed resistance to Trastuzumab (from Explanatory Sentence 1)\\nC: HER2 V777L can directly cause resistance to antibody therapies (from Explanatory Sentence 2)\\nD: resistance to Trastuzumab therapy (from Explanatory Sentence 3)\\nE: direct mechanisms involving HER2 V777L (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L is coincident with HER2-amplification in breast cancers, breast cancers have developed resistance to Trastuzumab)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L can directly cause resistance to antibody therapies, resistance to Trastuzumab therapy)\\n--------\\nImplies(E, D)\\nImplies(direct mechanisms involving HER2 V777L, resistance to Trastuzumab therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "5 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 states that HER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab. *)\\n(* This aligns with the logical proposition C. *)\\n(* We have a logical relation Implies(C, D), which implies that mechanisms involving HER2 V777L lead to resistance to antibody therapies. *)\\n(* From explanation 2, we can infer the existence of a cause event. *)\\nthen have \"\u2203e. Cause e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 104.3039276599884, 'proof tactics': [], 'code': 'theory clinical_106_5\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  HER2Amplification :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  Coincident :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  AntibodyTherapies :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  PrimaryFactor :: \"entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  Direct :: \"entity \u21d2 bool\"\\n  Involving :: \"event \u21d2 bool\"\\n  Occur :: \"event \u21d2 bool\"\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. HER2V777L x \u2227 HER2Amplification y \u2227 BreastCancer z \u2227 Coincident e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Resistance z \u2227 Trastuzumab z \u2227 Develop e2 \u2227 Agent e2 z\"\\n\\n(* Explanation 2: HER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab, by being a primary factor in mechanisms that lead to such resistance. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapies y \u2227 Trastuzumab y \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Mechanism z \u2227 PrimaryFactor z \u2227 Lead e2 \u2227 Agent e2 z \u2227 Patient e2 y\"\\n\\n(* Explanation 3: This patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. Resistance y \u2227 TrastuzumabTherapy y \u2227 Develop e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Mechanism z \u2227 Direct z \u2227 Involving e2 \u2227 Agent e2 z \u2227 Patient e2 x \u2227 HER2V777L x\"\\n\\n(* Explanation 4: Resistance to antibody therapies, including Trastuzumab, can occur due to mechanisms involving HER2 V777L. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1. Resistance x \u2227 AntibodyTherapies x \u2227 Trastuzumab x \u2227 Occur e1 \u2227 Agent e1 x \u2227 Mechanism y \u2227 Involving e1 \u2227 Agent e1 y \u2227 Patient e1 x \u2227 HER2V777L y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\"\\n  (* Hypothesis: HER2 V777L may cause resistance to antibody therapy *)\\n  shows \"\u2203x y e. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have the known information about HER2 V777L, resistance, and antibody therapy. *)\\n  from asm have \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\" <ATP>\\n  (* Explanation 2 states that HER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab. *)\\n  (* This aligns with the logical proposition C. *)\\n  (* We have a logical relation Implies(C, D), which implies that mechanisms involving HER2 V777L lead to resistance to antibody therapies. *)\\n  (* From explanation 2, we can infer the existence of a cause event. *)\\n  then have \"\u2203e. Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* Combining the known information and the inferred cause event, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L is coincident with HER2-amplification in breast cancers (from Explanatory Sentence 1)\\nB: breast cancers have developed resistance to Trastuzumab (from Explanatory Sentence 1)\\nC: HER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab (from Explanatory Sentence 2)\\nD: mechanisms involving HER2 V777L lead to resistance to antibody therapies, including Trastuzumab (from Explanatory Sentence 4)\\nE: this patient may develop resistance to Trastuzumab therapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L is coincident with HER2-amplification in breast cancers, breast cancers have developed resistance to Trastuzumab)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab, mechanisms involving HER2 V777L lead to resistance to antibody therapies, including Trastuzumab)\\n--------\\nImplies(D, E)\\nImplies(mechanisms involving HER2 V777L lead to resistance to antibody therapies, including Trastuzumab, this patient may develop resistance to Trastuzumab therapy)\\n--------\\n\\nDerived Implications:\\nImplies(C, E)\\nImplies(HER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab, this patient may develop resistance to Trastuzumab therapy)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(this patient may develop resistance to Trastuzumab therapy), Not(HER2 V777L can directly cause resistance to antibody therapies, including Trastuzumab))\\n--------\\n'}",
            "6 iteration: {'syntactic validity': True, 'error code': '(* Explanation 2 provides a logical relation that HER2 V777L can directly cause mechanisms leading to resistance to antibody therapies. *)\\n(* This implies that there exists a causal event involving HER2V777L and Resistance to AntibodyTherapy. *)\\n(* We can use this to infer the existence of a causal event. *)\\nfrom explanation_2 have \"\u2203e. Cause e \u2227 Agent e x \u2227 Patient e y\" sledgehammer', 'solving time': 104.2627944946289, 'proof tactics': [], 'code': 'theory clinical_106_6\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  HER2Amplification :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  Coincident :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Developed :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  PrimaryFactor :: \"entity \u21d2 entity \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  Involving :: \"entity \u21d2 entity \u21d2 bool\"\\n  Occur :: \"event \u21d2 bool\"\\n\\n(* Explanation 1: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e. HER2V777L x \u2227 HER2Amplification y \u2227 BreastCancer z \u2227 Coincident x y \u2227 Resistance z \u2227 Trastuzumab z \u2227 Developed e \u2227 Agent e z\"\\n\\n(* Explanation 2: HER2 V777L can directly cause mechanisms that lead to resistance to antibody therapies, including Trastuzumab, by being a primary factor in such mechanisms *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 Mechanism y \u2227 Resistance z \u2227 AntibodyTherapy z \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 PrimaryFactor x y\"\\n\\n(* Explanation 3: This patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. PatientEntity x \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 Mechanism z \u2227 HER2V777L z \u2227 Develop e \u2227 Agent e x \u2227 Patient e y \u2227 Involving z y\"\\n\\n(* Explanation 4: Resistance to antibody therapies, including Trastuzumab, can occur due to mechanisms involving HER2 V777L *)\\naxiomatization where\\n  explanation_4: \"\u2203x y e. Resistance x \u2227 AntibodyTherapy x \u2227 Trastuzumab x \u2227 Mechanism y \u2227 HER2V777L y \u2227 Occur e \u2227 Patient e x \u2227 Involving y x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\"\\n  (* Hypothesis: HER2 V777L may cause resistance to antibody therapy *)\\n  shows \"\u2203x y e. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y \u2227 Cause e \u2227 Agent e x \u2227 Patient e y\"\\nproof -\\n  (* From the premise, we have known information about HER2V777L, Resistance, and AntibodyTherapy. *)\\n  from asm have \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\" <ATP>\\n  (* Explanation 2 provides a logical relation that HER2 V777L can directly cause mechanisms leading to resistance to antibody therapies. *)\\n  (* This implies that there exists a causal event involving HER2V777L and Resistance to AntibodyTherapy. *)\\n  (* We can use this to infer the existence of a causal event. *)\\n  from explanation_2 have \"\u2203e. Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  (* Combining the known information and the inferred causal event, we can conclude the hypothesis. *)\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L is coincident with HER2-amplification in breast cancers (from Explanatory Sentence 1)\\nB: breast cancers have developed resistance to Trastuzumab (from Explanatory Sentence 1)\\nC: HER2 V777L can directly cause mechanisms leading to resistance to antibody therapies (from Explanatory Sentence 2)\\nD: resistance to antibody therapies, including Trastuzumab, occurs (from Explanatory Sentence 4)\\nE: this patient may develop resistance to Trastuzumab therapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L is coincident with HER2-amplification in breast cancers, breast cancers have developed resistance to Trastuzumab)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L can directly cause mechanisms leading to resistance to antibody therapies, resistance to antibody therapies, including Trastuzumab, occurs)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L can directly cause mechanisms leading to resistance to antibody therapies, this patient may develop resistance to Trastuzumab therapy)\\n--------\\n\\nDerived Implications:\\n'}",
            "7 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 11.638471364974976, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'verit found a proof...', 'cvc4 found a proof...', 'vampire found a proof...', 'verit: Try this: using explanation_2 by blast (3 ms)', 'zipperposition: Found duplicate proof', 'e found a proof...', 'cvc4: Found duplicate proof', 'e: Found duplicate proof', 'cvc4: Found duplicate proof', 'vampire: Found duplicate proof', 'Done'], 'code': 'theory clinical_106_7\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  HER2V777L :: \"entity \u21d2 bool\"\\n  HER2Amplification :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  Coincident :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Patient :: \"event \u21d2 entity \u21d2 bool\"\\n  In :: \"entity \u21d2 entity \u21d2 bool\"\\n  Resistance :: \"entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Develop :: \"event \u21d2 bool\"\\n  CausalEvent :: \"entity \u21d2 bool\"\\n  AntibodyTherapies :: \"entity \u21d2 bool\"\\n  Cause :: \"event \u21d2 bool\"\\n  Lead :: \"event \u21d2 bool\"\\n  PrimaryFactor :: \"entity \u21d2 bool\"\\n  PatientEntity :: \"entity \u21d2 bool\"  (* Renamed to avoid conflict with Patient predicate *)\\n  TrastuzumabTherapy :: \"entity \u21d2 bool\"\\n  Mechanism :: \"entity \u21d2 bool\"\\n  Involve :: \"event \u21d2 bool\"\\n  Occur :: \"event \u21d2 bool\"\\n  AntibodyTherapy :: \"entity \u21d2 bool\"\\n\\n(* Explanation 1: HER2 V777L is coincident with HER2-amplification in breast cancers that have developed resistance to Trastuzumab. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. HER2V777L x \u2227 HER2Amplification y \u2227 BreastCancer z \u2227 Coincident e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 In y z \u2227 Resistance z \u2227 Trastuzumab z \u2227 Develop e2 \u2227 Agent e2 z\"\\n\\n(* Explanation 2: HER2 V777L can directly cause a specific causal event that leads to resistance to antibody therapies, including Trastuzumab, by being a primary factor in such mechanisms. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z e1 e2. HER2V777L x \u2227 CausalEvent y \u2227 Resistance z \u2227 AntibodyTherapies z \u2227 Trastuzumab z \u2227 Cause e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Lead e2 \u2227 Agent e2 y \u2227 Patient e2 z \u2227 PrimaryFactor x\"\\n\\n(* Explanation 3: This patient may develop resistance to Trastuzumab therapy due to direct mechanisms involving HER2 V777L. *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e1 e2. PatientEntity x \u2227 Resistance y \u2227 TrastuzumabTherapy y \u2227 Mechanism z \u2227 HER2V777L z \u2227 Develop e1 \u2227 Agent e1 x \u2227 Patient e1 y \u2227 Involve e2 \u2227 Agent e2 z \u2227 Patient e2 y\"\\n\\n(* Explanation 4: Resistance to antibody therapies, including Trastuzumab, can occur due to mechanisms involving HER2 V777L. *)\\naxiomatization where\\n  explanation_4: \"\u2203x y z e1 e2. Resistance x \u2227 AntibodyTherapies x \u2227 Trastuzumab x \u2227 Mechanism y \u2227 HER2V777L y \u2227 Occur e1 \u2227 Agent e1 x \u2227 Involve e2 \u2227 Agent e2 y \u2227 Patient e2 x\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\"\\n  (* Hypothesis: HER2 V777L may cause resistance to antibody therapy *)\\n  shows \"\u2203x y e. HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y \u27f6 (Cause e \u2227 Agent e x \u2227 Patient e y)\"\\nproof -\\n  (* From the premise, we have known information about HER2 V777L, Resistance, and Antibody Therapy. *)\\n  from asm have \"HER2V777L x \u2227 Resistance y \u2227 AntibodyTherapy y\" <ATP>\\n  (* There is a logical relation Implies(C, D), which states that HER2 V777L can directly cause a specific causal event leading to resistance to antibody therapies, and resistance to antibody therapies, including Trastuzumab, occurs. *)\\n  (* Explanation 2 provides the causal link between HER2 V777L and resistance to antibody therapies. *)\\n  (* We can use this to infer the existence of a causal event. *)\\n  then have \"\u2203e. Cause e \u2227 Agent e x \u2227 Patient e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: HER2 V777L is coincident with HER2-amplification in breast cancers (from Explanatory Sentence 1)\\nB: breast cancers have developed resistance to Trastuzumab (from Explanatory Sentence 1)\\nC: HER2 V777L can directly cause a specific causal event leading to resistance to antibody therapies (from Explanatory Sentence 2)\\nD: resistance to antibody therapies, including Trastuzumab, occurs (from Explanatory Sentence 4)\\nE: this patient may develop resistance to Trastuzumab therapy (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(HER2 V777L is coincident with HER2-amplification in breast cancers, breast cancers have developed resistance to Trastuzumab)\\n--------\\nImplies(C, D)\\nImplies(HER2 V777L can directly cause a specific causal event leading to resistance to antibody therapies, resistance to antibody therapies, including Trastuzumab, occurs)\\n--------\\nImplies(C, E)\\nImplies(HER2 V777L can directly cause a specific causal event leading to resistance to antibody therapies, this patient may develop resistance to Trastuzumab therapy)\\n--------\\n\\nDerived Implications:\\n'}"
        ]
    }
}